New research suggests that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Published data in a prominent health publication demonstrates that while obese people frequently drop substantial amounts of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.
"People purchasing such drugs need to be cognizant of the risk of quick rebound weight gain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
That rate of recovery means a reversion to original weight in about one and a half years.
Analyzing Approaches
The study, which looked at dozens of trials involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone usually experience a more gradual weight regain—approximately 100 grams monthly—after stopping.
Understanding the Fast Regain
Nutrition scientists believe the mechanism of the injections is key to understanding the amplified weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement means hunger is unsuppressed, making excessive eating much more probable."
An Ongoing Issue?
Health authorities advise the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Many experts contend that, due to the high risk of relapse, the treatment might need to be life-long.
This opinion is supported by pharmaceutical companies, who say that the results "underscore the chronic character of excess weight," similar to managing diseases like high blood pressure.
Patient Testimonies
People who have come off the medication explain a powerful resurgence of hunger.
"It felt as if something that goes on and you become ravenous," recalled one woman.
This challenge is exacerbated if individuals have not established lasting dietary or behavioural modifications during therapy.
Growing Interest
Survey data suggest that a significant number of adults in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is greater among women than males.
- The 40s and 50s demographic shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while the jabs are effective tools for weight loss, they are not a magic cure and maintained weight loss hinges on integrated behavioural management.
